LCK
MOLECULAR TARGETLCK proto-oncogene, Src family tyrosine kinase
LCK (LCK proto-oncogene, Src family tyrosine kinase) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting LCK
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Sorafenib | 2.08 | 7 |
| 2 | Crizotinib | 1.79 | 5 |
| 3 | Dasatinib | 1.61 | 4 |
| 4 | kenpaullone | 1.39 | 3 |
| 5 | Acetic Acid Product of | 1.10 | 2 |
| 6 | Afatinib | 0.69 | 1 |
| 7 | Axitinib | 0.69 | 1 |
| 8 | piceatannol | 0.69 | 1 |
| 9 | sp600125 | 0.69 | 1 |
| 10 | Swainsonine | 0.69 | 1 |
| 11 | tyrphostin ag 1478 | 0.69 | 1 |
About LCK as a Drug Target
LCK (LCK proto-oncogene, Src family tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented LCK interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
LCK inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.